Insulin pumps: more consultation was needed

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7521.905-c (Published 13 October 2005) Cite this as: BMJ 2005;331:905
  1. Andrew J Palmer (ap@thecenter.ch), director, medical research,
  2. Daniel M D Tucker, health economist,
  3. Joshua A Ray, health economist,
  4. William J Valentine, health economist,
  5. Craig Currie, honorary research fellow in diabetes, endocrinology, and metabolism,
  6. Phil McEwan, director,
  7. Michael Brändle, director
  1. CORE—Centre for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen, Switzerland
  2. Department of Medicine, Cardiff University, University Hospital of Wales, Cardiff CF14 4UJ
  3. School of Mathematics, Cardiff University, Cardiff CF14 4UJ
  4. Division of Endocrinology and Diabetes, Department of Internal Medicine, Kantonsspital St Gallen, Switzerland

    EDITOR—Colquitt et al recently published a health technology assessment on the clinical and cost effectiveness of continuous subcutaneous insulin infusion for diabetes for the National Institute for Health and Clinical Excellence (NICE).1 Believing that some important issues needed to be communicated with other readers, we contacted the NHS Health Technology Assessment Programme and were informed that its journal does not offer the opportunity to respond to previous appraisals in forthcoming publications (although the programme's website offers a forum for discussion, at www.ncchta.org/correspond/).

    Given the potential impact of such publications in …

    View Full Text

    Sign in

    Log in through your institution